Skip to main content
OpenTrials
Completed

NCT Number: NCT01453400

Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain

This study is to evaluate the onset of relief provided by a single, oral dose of fast release aspirin 1000 mg compared to acetaminophen 1000 mg and placebo in subjects with sore throat pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Storrs, Connecticut, 06269-2011, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, ambulatory, male and female subjects ≥ 18 years of age
  • Presence of sore throat due to upper respiratory tract infection (URTI)
  • Onset of sore throat pain within six days of the screening period
  • Baseline sore throat pain intensity score ≥ 60 mm on the Sore Throat Pain Intensity Scale
  • Have a score ≥ 5 on the Tonsillopharyngitis Assessment
  • Female subjects of childbearing potential who are currently sexually active must be using a medically acceptable form of birth control for at least one month prior to screening (three months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Nuvaring, Depo-Provera, or double-barrier and have a negative pregnancy test at screening/treatment period. Female subjects of non-childbearing potential must be amenorrheic for at least two years or had a hysterectomy and/or bilateral oophorectomy.
  • Understand the pain rating assessments

Exclusion criteria

  • History of hypersensitivity to aspirin, salicylates, other nonsteroidal anti-inflammatory drugs, acetaminophen, opioid analgesics, and similar drugs
  • Use of any "cold medication" (i.e. decongestants, antihistamines, expectorants, antitussives) within four hours preceding administration of the investigational product
  • Use of any immediate release analgesic/antipyretic within four hours or use of any sustained release or long-acting analgesic/antipyretic within twelve hours preceding administration of the investigational product
  • Consumption of alcoholic beverages, or foods and beverages containing xanthines within two hours prior to administration of the investigational product
  • Use of any sore throat lozenges, sprays, cough drops, menthol-containing products within one hour preceding administration of the investigational product
  • Presence of cough that causes throat discomfort
  • Presence of mouth-breathing or any respiratory condition that, in the Investigator's judgment, could compromise breathing
  • Evidence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies for which aspirin or acetaminophen is contraindicated
  • Relevant concomitant disease such as medically uncontrolled asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than fifty percent obstruction
  • History of gastrointestinal bleeding or perforation related to previous non-steroidal anti-inflammatory therapy.
  • Current or past history of a bleeding disorder
  • Self reported alcoholism or drug abuse within two years prior to screening or routine consumption of three or more alcohol containing beverages per day
  • Habituation to analgesic drugs or tranquilizers (i.e., routine use of five or more times per week for greater than three weeks)
  • Acute illness, local infection, or disease (other than URTI with pharyngeal infection) that can interfere with the conduct of the study
  • Current use of blood thinning (anticoagulant), low dose aspirin, or steroid drug
  • Has initiated treatment for depression within the past thirty days
  • Females who are pregnant or lactating

Treatment and study plan

Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo

Drug

Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets

Acetaminophen + placebo

Drug

Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets

Placebo

Drug

Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets

Primary outcomes

  1. Time to meaningful pain relief from the Sore Throat Pain Intensity Scale (STPIS) 100 mm visual analog scale

    Time frame: Up to two hours

Secondary outcomes

  1. Global assessment of the investigational product as a pain reliever by grading from 0 to 4 (from poor to excellent)

    Time frame: Two hours postdose or immediately before the intake of rescue medication

  2. Time to first perceptible relief (defined as the time when the subject presses the first stopwatch)

    Time frame: Up to two hours

  3. Time weighted sum of pain intensity differences (PID) scores over first hour

    Time frame: Up to one hour

  4. Time weighted sum of pain intensity differences (PID) scores over 2 hours

    Time frame: Up to two hours

  5. Percentage difference from baseline Sore Throat Pain Intensity Scale (STPIS) to STPIS at time of meaningful relief

    Time frame: Up to two hours

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Onset of Action of a Fast Release Aspirin Tablet and Acetaminophen Caplet in Sore Throat Pain

Acronym: Tarot

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Oct 17, 2011
Registry last updated
Dec 7, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.